Carcinogenesis Advance Access originally published online on September 29, 2005
Carcinogenesis 2006 27(3):525-532; doi:10.1093/carcin/bgi227
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis vol.27 no.3 © Oxford University Press 2005; all rights reserved.
CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung
1 Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia and 2 School of Medicine, University of Queensland, Brisbane, Australia
* To whom correspondence and reprint requests should be addressed. Tel: +61 733 508111; Fax: +61 733 508957; Email: kwun_fong{at}health.qld.gov.au
Common polymorphisms in genes encoding phase I and phase II enzymes are considered to modify lung cancer risk due to changes in enzyme activity. Candidates include genetic variants of glutathione S-transferases (GSTM1, GSTT1 and GSTP1) and myeloperoxidase (MPO). We performed a large case–control study of these candidate genes in 1103 patients with non-small cell lung cancer (NSCLC) and 627 controls without NSCLC. Associations between deletion genotypes of GSTM1 and GSTT1 and between single nucleotide polymorphisms (SNPs) of GSTP1 Ile105Val and MPO G-463A were first tested by adjusted logistic regression. Then we analysed gene–gene interactions, also incorporating our published data on the Ile462Val SNP in the phase I enzyme, cytochrome P450 CYP1A1. The homozygous GSTP1 105Val genotype was significantly under-represented in NSCLC compared with controls (OR = 0.73; 95%CI 0.53–1.00; P = 0.050), especially in females (OR = 0.57; 95%CI 0.34–0.98; P = 0.04). The GSTT1-null genotype was significantly over-represented in adenocarcinomas (OR = 1.41; 95%CI 1.06–1.90; P = 0.02) but not in squamous cell carcinomas (OR = 1.03; 95%CI 0.76–1.41; P = 0.84). There was weak risk reduction associated with GSTM1 null in heavy smokers (OR = 0.71; 95%CI 0.54–0.94; P = 0.02), but neither GSTM1 nor MPO genotypes affected the overall risk of NSCLC. The MPO and CYP1A1 risk genotypes interacted to increase the overall risk of NSCLC (OR = 2.88; 95%CI 1.70–5.00; P < 0.001). The data are consistent with the concept that multiple genes of modest effect interact to confer genomic-based susceptibility to lung cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. L. Cote, W. Chen, D. W. Smith, S. Benhamou, C. Bouchardy, D. Butkiewicz, K. M. Fong, M. Gene, A. Hirvonen, C. Kiyohara, et al. Meta- and Pooled Analysis of GSTP1 Polymorphism and Lung Cancer: A HuGE-GSEC Review Am. J. Epidemiol., April 1, 2009; 169(7): 802 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I A Yang, K M Fong, P V Zimmerman, S T Holgate, and J W Holloway Genetic susceptibility to the respiratory effects of air pollution Thorax, June 1, 2008; 63(6): 555 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kohno, H. Kunitoh, K. Suzuki, S. Yamamoto, A. Kuchiba, Y. Matsuno, N. Yanagitani, and J. Yokota Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias Carcinogenesis, May 1, 2008; 29(5): 957 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vineis, S. Anttila, S. Benhamou, M. Spinola, A. Hirvonen, C. Kiyohara, S. J. Garte, R. Puntoni, A. Rannug, R. C. Strange, et al. Evidence of gene gene interactions in lung carcinogenesis in a large pooled analysis Carcinogenesis, September 1, 2007; 28(9): 1902 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-A. Yoon, S. Park, B. Hwangbo, H. D. Shin, H. S. Cheong, H.-R. Shin, and J. S. Lee Genetic polymorphisms in the Rb-binding zinc finger gene RIZ and the risk of lung cancer Carcinogenesis, September 1, 2007; 28(9): 1971 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Vineis, F Veglia, S Garte, C Malaveille, G Matullo, A Dunning, M Peluso, L Airoldi, K Overvad, O Raaschou-Nielsen, et al. Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers Ann. Onc., July 1, 2007; 18(7): 1230 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Amal Al Omari and D. J. Murry Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance Journal of Pharmacy Practice, June 1, 2007; 20(3): 206 - 218. [Abstract] [PDF]
|
|
|
|
|
|
J. Yang, C. B. Ambrosone, C.-C. Hong, J. Ahn, C. Rodriguez, M. J. Thun, and E. E. Calle Relationships between polymorphisms in NOS3 and MPO genes, cigarette smoking and risk of post-menopausal breast cancer Carcinogenesis, June 1, 2007; 28(6): 1247 - 1253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Schwartz, G. M. Prysak, C. H. Bock, and M. L. Cote The molecular epidemiology of lung cancer Carcinogenesis, March 1, 2007; 28(3): 507 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-A. Yoon, B. Hwangbo, I.-J. Kim, S. Park, H. S. Kim, H. J. Kee, J. E. Lee, Y. K. Jang, J.-G. Park, and J. S. Lee Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer Carcinogenesis, November 1, 2006; 27(11): 2217 - 2222. [Abstract] [Full Text] [PDF]
|
|